Amisulpride

Spezifikationen

71675-85-9CAS-Nummer

275-831-7EG-Nummer

4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamideIUPAC-Name

C17H27N3O4SChemische Formel

369.5 g/molMolekulargewicht

amisulpride; 71675-85-9; Solian; Aminosultopride; Deniban; Amisulprida; Amisulpridum; Socian; Barhemsys; 4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; Sulamid; APD421; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide; DAN-2163; DTXSID5042613; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide; NSC-760085; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide; APD-421; 8110R61I4U; DTXCID3022613; CHEBI:64045; 4-amino-5-(ethanesulfonyl)-N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxybenzamide; Benzamide, 4-amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxy-; 4-amino-5-(ethanesulfonyl)-N-((1-ethylpyrrolidin-2-yl)methyl)-2-methoxybenzamide; 4-amino-N-((1-ethylpyrrolidin-2-yl)methyl)-5-ethylsulfonyl-2-methoxybenzamide; Solian 50; Solian 100; Solian 200; Solian 400; RefChem:56544; N05AL05; 275-831-7; Amisulpiride; DAN 2163; Amisulpride [INN]; C17H27N3O4S; Amisulpride free base; MFCD00866691; Amisulpride (INN); 4-amino-N-((1-ethylpyrrolidin-2-yl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide; S-Amisulpride; R-Amisulpride; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; NCGC00092310-03; Amisulpridum [INN-Latin]; Amisulprida [INN-Spanish]; Sulpitac; SMR000449309; Deniban (TN); CAS-71675-85-9; Solian (TN); Amisulpride [INN:BAN]; EINECS 275-831-7; Amisulpride?; Aminosultopride;; Amisulpride CRS; Deniban;; Enorden;; Majorem;; Socian;; UNII-8110R61I4U; Barhemsys (TN); 71675-85-9 (free base); 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-anisamid; Amisulpride; 4-Amino-N-[[(2RS)-1-ethylpyrrolidin-2-yl]methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; (S)-Amisulpride?; (plusmn)-amisulpride; PS24 - Amisulpride; Amisulpride (Standard); AMISULPRIDE [MI]; SL-91.1077; AMISULPRIDE [MART.]; SCHEMBL34126; (+/-)-AMISULPRIDE; AMISULPRIDE [WHO-DD]; GTPL963; MLS000758258; MLS000759450; MLS001424039; MLS006011769; CHEMBL243712; orb1224161; orb1310270; orb3141195; Amisulpride - Bio-X trade mark; SCHEMBL29506665; Amisulpride, >=98% (HPLC); Amisulpride, 1mg/ml in Methanol; BDBM81790; AMISULPRIDE [ORANGE BOOK]; Amisulpride for system suitability; AMISULPRIDE [EP MONOGRAPH]; HMS2051K10; HMS2235M16; HMS3263D07; HMS3268L09; HMS3369K09; HMS3393K10; HMS3413G07; HMS3657E11; HMS3677G07; HMS3713N06; HMS3884A09; HMS5079J05; Pharmakon1600-01502285; MSK10508; NSC_2159; WCA67590; WCA67592; Tox21_113392; Tox21_501133; EBC-11187; HB1879; HY-14545R; NSC760085; STK635172; AKOS005567252; Amisulpride for system suitability CRS; Tox21_113392_1; AC-6820; CCG-100860; CCG-220622; CCG-222437; CS-1791; DB06288; FA17868; LP01133; NC00110; NSC 760085; SDCCGSBI-0633795.P001; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxy-benzamide; NCGC00092310-01; NCGC00092310-02; NCGC00092310-04; NCGC00092310-06; NCGC00092310-13; NCGC00092310-16; NCGC00261818-01; AS-13890; BA164158; HY-14545; SY052770; Amisulpride 100 microg/mL in Acetonitrile; CAS_71675-85-9; A2450; A5234; NS00000416; S1280; SW197490-3; D07310; AB00639933-07; AB00639933-09; AB00639933_10; EN300-18166870; F813427; L000106; Q418785; SR-01000759303; SR-01000759303-5; BRD-A60197193-001-05-4; BRD-A60197193-001-13-8; BRD-A60197193-001-14-6; Amisulpride, British Pharmacopoeia (BP) Reference Standard; Amisulpride, European Pharmacopoeia (EP) Reference Standard; 4-Amino-N-[(1-ethyl-2-pyrrolidinyl) methyl]-5-(ethylsulfonyl)-2-benzamide; 4-amino-5-ethanesulfonyl-n-(1-ethyl-pyrrolidin-2-ylmethyl)-2-methoxy-benzamide; 4-Amino-N-[(1-Ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)- 2-methoxybenzamide; 4-amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-ethylsulfonyl-2-methoxybenzamide; Amisulpride for system suitability, European Pharmacopoeia (EP) Reference Standard; AmisulpiridSynonyme